You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Nucleophosmin 1 Mutation

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Relapsed/Refractory Leukemias, Acute Lymphoblastic Leukemia, Acute Lymphocytic Leukemia Trial in Kansas City, Cincinnati

Recruiting
  • Relapsed/Refractory Leukemias
  • +4 more
  • Kansas City, Missouri
  • +1 more
Jul 18, 2022

Leukemia, Myeloid, Acute, Leukemia, Lymphocytic, Acute Trial in Japan, United States (DSP-5336)

Recruiting
  • Leukemia, Myeloid, Acute
  • Leukemia, Lymphocytic, Acute
  • Houston, Texas
  • +5 more
May 31, 2022

Acute Myeloid Leukemia Trial in Austria, Germany (Gemtuzumab Ozogamicin (Mylotarg), standard chemo)

Completed
  • Acute Myeloid Leukemia
  • Gemtuzumab Ozogamicin (Mylotarg)
  • standard chemotherapy
  • Graz, Austria
  • +59 more
Sep 28, 2021

AXIN1 Gene Mutation, APC Gene Mutation, Solid Tumor Trial (REC-4881)

Not yet recruiting
  • AXIN1 Gene Mutation
  • +2 more
  • (no location specified)
Aug 21, 2023

Aumolertinib, Anlotinib, TP53 Trial (Aumolertinib,Anlotinib)

Not yet recruiting
  • Aumolertinib
  • +4 more
  • (no location specified)
Mar 8, 2023

Cholangiocarcinoma Non-resectable, Cholangiocarcinoma Metastatic Trial (Ivosidenib)

Not yet recruiting
  • Cholangiocarcinoma Non-resectable
  • Cholangiocarcinoma Metastatic
  • (no location specified)
Oct 10, 2023

Non Small Cell Lung Cancer, Immune Checkpoint Inhibitor, EGFR Exon 21 Mutation Trial in Peking (Pembrolizumab, pemetrexed,

Not yet recruiting
  • Non Small Cell Lung Cancer
  • +2 more
  • Peking, China
    Peking Union Medical College Hospital
Nov 16, 2023

Autosomal Dominant Optic Atrophy (ADOA), Caused by OPA1 Mutation

Not yet recruiting
  • Autosomal Dominant Optic Atrophy
  • +3 more
    • Sydney, Australia
      Sydney Eye Hospital
    Nov 15, 2023

    Locally Advanced or Metastatic KRAS G12C-mutated NSCLC With a PD-L1 Expression <1% or a PD-L1 Expression = 1% and an STK11

    Recruiting
    • Locally Advanced or Metastatic KRAS G12C-mutated NSCLC With a PD-L1 Expression <1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation
    • Montpellier, France
    • +7 more
    Dec 19, 2022

    Retinal Dystrophy, PRPF31 Mutationassociated Retinal Dystrophy, RP11 Trial in Dallas (VP-001)

    Recruiting
    • Retinal Dystrophy
    • +2 more
    • Dallas, Texas
      Retina Foundation of the Southwest
    Jun 5, 2023

    Gene Mutation Trial in Beijing (RAG-17)

    Enrolling by invitation
    • Gene Mutation
    • Beijing, China
      Beijing Tiantan Hospital
    Jun 11, 2023

    An Intervention to Increase Genetic Testing in Families Who May

    Recruiting
    • BRCA1 Mutation
    • +21 more
    • Intervention Arm At-risk Relative/ARR Contacts
    • +5 more
    • Basking Ridge, New Jersey
    • +7 more
    Nov 22, 2022

    Nucleophosmin 1-mutated Acute Myeloid Leukemia Trial in Worldwide (Entospletinib, Placebo, Cytarabine)

    Recruiting
    • Nucleophosmin 1-mutated Acute Myeloid Leukemia
    • Duarte, California
    • +60 more
    Jul 20, 2022

    NSCLC Metastatic Trial in Stockholm (Stereotactic body radiation therapy (SBRT), Temporary Stopping)

    Recruiting
    • Non-small Cell Lung Cancer Metastatic
    • Stereotactic body radiation therapy (SBRT)
    • Temporary Stopping
    • Stockholm, Solna, Sweden
      Karolinska University Hospital
    Nov 9, 2023

    Solid Tumor, ARID1A Gene Mutation Trial in Greenville (Tazemetostat)

    Suspended
    • Solid Tumor
    • ARID1A Gene Mutation
    • Greenville, South Carolina
      Prisma Health Cancer Institute
    Jan 10, 2023

    Breast Cancer, Genetic Predisposition Trial in Rome, Varese (Genetic predisposition to breast cancer)

    Recruiting
    • Breast Cancer
    • Genetic Predisposition
    • Genetic predisposition to breast cancer
    • Rome, Italy
    • +1 more
    May 4, 2023

    Metastatic Solid Tumor, SF3B1 Gene Mutation, Spliceosome Mutation Trial in Baltimore (Recommendation for treatment with

    Recruiting
    • Metastatic Solid Tumor
    • +4 more
    • Recommendation for treatment with immunotherapy
    • Baltimore, Maryland
      Johns Hopkins University
    Sep 8, 2022

    Solid Tumor, Advanced Solid Tumor, NSCLC Trial (MRTX1133)

    Not yet recruiting
    • Solid Tumor
    • +4 more
    • (no location specified)
    Feb 21, 2023

    Rectal Cancer Trial (PD-1, SCRT, Bevacizumab)

    Not yet recruiting
    • Rectal Cancer
    • (no location specified)
    Dec 6, 2022

    Advanced Solid Tumors Trial in Chengdu (GEC255 tablets)

    Recruiting
    • Advanced Solid Tumors
    • GEC255 tablets
    • Chengdu, Sichuan, China
      China West Hospital
    Mar 14, 2023

    Advanced Solid Tumor, Metastatic Solid Tumor, NSCLCs Trial (PRT3789)

    Recruiting
    • Advanced Solid Tumor
    • +3 more
    • Fairfax, Virginia
      NEXT Virginia
    Feb 1, 2023

    NSCLC, Non-small Cell Carcinoma, Histiocytic Tumor Trial (BDTX-4933)

    Not yet recruiting
    • Non-small Cell Lung Cancer
    • +32 more
    • (no location specified)
    Mar 30, 2023

    Advanced Malignant Solid Tumor, EGFR Gene Amplification, EGFR Gene Mutation Trial in Houston (Everolimus, Neratinib,

    Recruiting
    • Advanced Malignant Solid Neoplasm
    • +9 more
    • Houston, Texas
      M D Anderson Cancer Center
    Oct 25, 2022

    BRCA1/2 Flu Vaccine

    Active, not recruiting
    • BRCA1 Mutation
    • BRCA2 Mutation
    • Seasonal influenza vaccine
    • Philadelphia, Pennsylvania
      University of Pennsylvania
    Aug 16, 2022

    The Prevelence of IVS 1-6 [HBB:c.92 +6 T-C] Gene Mutation in

    Not yet recruiting
    • Beta-Thalassemia
    • ARMS
    • (no location specified)
    May 10, 2022